The former included patients NYHA class II–IV, with LVEF ≤ 40% despite OMT, and elevated NT-proBNP, and randomly assigned in a 1:1 ratio to receive dapagliflozin 10 mg or placebo on top of optimal medical therapy: a 26% risk reduction rate of worsening HF and CV death was observed, and, in addition, dapagliflozin did improve symptoms, physical function, and quality of life [31]. Here, NPPB is linked to hydrops fetalis.